
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Diagnosis and Treatment of Hemochromatosis</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Diagnosis and Treatment of Hemochromatosis</strong></summary>
            <div>
                <ul><li>Authors: Paul C. Adams, John D. Ryan</li><li>Journal: Clinical Gastroenterology and Hepatology</li><li>Publication Date: 2025</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>1. What is the estimated risk for a male C282Y homozygote to develop severe liver disease if left untreated?</li><li>2. A serum ferritin &gt;1000 mg/L is a critical threshold. What is the approximate risk of advanced liver fibrosis (F3/F4) in C282Y homozygotes who exceed this level?</li><li>3. What is the negative predictive value (NPV) of having both a normal serum ferritin and a transferrin saturation &lt;45% for ruling out hemochromatosis?</li><li>4. Beyond the liver, male C282Y homozygotes have a significantly increased risk for another common condition. What is the odds ratio for osteoporosis in this group?</li><li>5. What is the most common cause of an elevated serum ferritin in the general population?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Introduction &amp; Overview</strong></summary>
            <div>
                <ul><li>Hemochromatosis: a common genetic disease of iron overload.</li><li>Focus on C282Y homozygotes in the HFE gene.</li><li>Emphasizes need for earlier diagnosis &amp; treatment to prevent complications.</li></ul>
                
        <details>
            <summary><strong>Historical Context</strong></summary>
            <div>
                <ul><li>Genetic variants identified in 4000-year-old human fossils in North Western Europe.</li><li>Postulated to promote iron absorption as a survival benefit.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Clinical Significance</strong></summary>
            <div>
                <ul><li>Excess iron absorption → serious complications.</li><li>Early diagnosis &amp; treatment can prevent morbidity &amp; mortality.</li></ul>
                
        <details>
            <summary><strong>Key Complications</strong></summary>
            <div>
                <ul><li>Arthritis</li><li>Liver fibrosis &amp; cirrhosis</li><li>Primary liver cancer (HCC)</li><li>Diabetes</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Epidemiology</strong></summary>
            <div>
                <ul><li>Most common genetic disease in persons of European ancestry.</li></ul>
                
        <details>
            <summary><strong>Prevalence of C282Y Homozygosity</strong></summary>
            <div>
                <ul><li>North America (HEIRS study): 1 in 227</li><li>Northern England (UK Biobank): 1 in 156</li><li>Ireland: ≈1% (highest in the world)</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Clinical Penetrance</strong></summary>
            <div>
                <ul><li>Not absolute, but significant morbidity risk.</li><li>UK Biobank data:</li><li>- 1 in 5 males develop morbidity.</li><li>- 1 in 10 females develop morbidity.</li></ul>
                
        <details>
            <summary><strong>Severe Liver Disease Risk</strong></summary>
            <div>
                <ul><li>1 in 10 males will develop severe liver disease if not identified early &amp; treated.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnosis</strong></summary>
            <div>
                <ul><li>Challenging due to non-specific signs &amp; symptoms.</li><li>Diagnosis often delayed until 40s in men or 50s in women.</li><li>Relies heavily on biochemical and genetic testing.</li></ul>
                
        <details>
            <summary><strong>Clinical Presentation</strong></summary>
            <div>
                <ul><li>Symptoms are non-specific &amp; often absent in early stages.</li><li>Diagnosis is frequently incidental.</li></ul>
                
        <details>
            <summary><strong>Common Symptoms</strong></summary>
            <div>
                <ul><li>Fatigue &amp; arthralgias of the knuckles: affect &gt;50% of individuals.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnostic Triggers</strong></summary>
            <div>
                <ul><li>Family history of hemochromatosis.</li><li>Incidental finding of ↑ serum ferritin or ↑ transferrin saturation.</li><li>Incidental MRI finding of a &#x27;black liver&#x27; due to iron overload.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>The Underdiagnosis Problem</strong></summary>
            <div>
                <ul><li>UK Biobank study: only 12% of male &amp; 3.4% of female C282Y homozygotes had a prior diagnosis.</li><li>Average age at diagnosis: 58.5 years (women), 61 years (men).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Interpretation of Iron Studies</strong></summary>
            <div>
                <ul><li>Diagnostic Paradox: Most cases are missed (missed diagnosis), yet hemochromatosis is also frequently over-diagnosed (misdiagnosis) in patients with elevated ferritin from other causes.</li></ul>
                
        <details>
            <summary><strong>Serum Ferritin</strong></summary>
            <div>
                <ul><li>Non-specific test; elevation is extremely common.</li><li>HEIRS study: 13% of participants had elevated ferritin.</li><li>Probability of C282Y homozygosity ↑ as ferritin level ↑.</li></ul>
                
        <details>
            <summary><strong>Common Causes of Hyperferritinemia</strong></summary>
            <div>
                <ul><li>Metabolic hyperferritinemia is the most common cause.</li><li>- Metabolic syndrome</li><li>- Fatty liver</li><li>- Daily alcohol use</li><li>- Obesity</li><li>- Inflammation</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Transferrin Saturation</strong></summary>
            <div>
                <ul><li>Reflects daily iron absorption.</li><li>Poor reproducibility &amp; significant biological variability (circadian rhythm).</li><li>Best measured fasting &amp; on more than one occasion.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendations for HFE Testing</strong></summary>
            <div>
                <ul><li>Warranted when:</li><li>- Serum ferritin &gt;200 mg/L (women) or &gt;300 mg/L (men)</li><li>- AND Transferrin saturation &gt;45%</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Ruling Out Hemochromatosis</strong></summary>
            <div>
                <ul><li>Combination of normal serum ferritin &amp; transferrin saturation &lt;45%.</li><li>Provides a Negative Predictive Value (NPV) of 97%.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Initial Workup in C282Y Homozygote</strong></summary>
            <div>
                <ul><li>Full blood count, LFTs (AST, ALT), bilirubin, creatinine.</li><li>Fasting blood glucose, HbA1c.</li><li>Alpha-fetoprotein (AFP), abdominal ultrasound.</li><li>Consider fibrosis biomarkers (FIB-4, APRI) or elastography.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Genetic Testing for HFE C282Y</strong></summary>
            <div>
                <ul><li>Confirms the diagnosis.</li><li>Test is reproducible, inexpensive (as low as $5), and can be done on saliva.</li></ul>
                
        <details>
            <summary><strong>Screening Considerations</strong></summary>
            <div>
                <ul><li>Economic analyses show cost-effectiveness.</li><li>Logistical challenges exist; mail-back programs have low uptake.</li><li>Whole genome sequencing may increase detection in the future.</li></ul>
                
        <details>
            <summary><strong>ACMG Recommendation</strong></summary>
            <div>
                <ul><li>Hemochromatosis is a Tier 1 genetic result.</li><li>Notification of the result to the patient is recommended.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Approach to a New Diagnosis</strong></summary>
            <div>
                <ul><li>Involves family screening &amp; risk stratification based on iron burden.</li></ul>
                
        <details>
            <summary><strong>Family Screening</strong></summary>
            <div>
                <ul><li>Siblings &amp; parents should be tested for HFE (C282Y).</li><li>Adult children may be tested, or their other parent can be tested first.</li><li>Screening of non-adult children is not recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Role of Serum Ferritin</strong></summary>
            <div>
                <ul><li>Best noninvasive marker of iron burden at diagnosis.</li><li>Predicts likelihood of complications &amp; number of phlebotomies needed.</li><li>Key indicator of liver disease risk.</li></ul>
                
        <details>
            <summary><strong>Ferritin &gt;1000 mg/L</strong></summary>
            <div>
                <ul><li>Significantly increases likelihood of severe liver fibrosis.</li><li>One study: 1 in 5 patients with ferritin &gt;1000 mg/L (and/or ↑ transaminases) had advanced (F3/F4) fibrosis on biopsy.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Liver Fibrosis Assessment</strong></summary>
            <div>
                <ul><li>All patients should be screened.</li><li>Liver disease affects ≈20% of adult male C282Y homozygotes.</li></ul>
                
        <details>
            <summary><strong>Imaging</strong></summary>
            <div>
                <ul><li>Baseline abdominal ultrasound: assess for steatosis, cirrhosis, portal hypertension, HCC.</li><li>MRI: Not required for diagnosis in C282Y homozygotes, but accurately quantifies iron burden in non-HFE cases.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Non-Invasive Markers</strong></summary>
            <div>
                <ul><li>Blood-based scores (FIB-4, APRI) can be used.</li><li>- APRI &gt;0.44 or FIB-4 &gt;1.1: Good ability to detect advanced fibrosis.</li><li>- APRI &lt;0.37 or FIB-4 &lt;0.73: High NPV (88.6-92%) for advanced fibrosis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Transient Elastography</strong></summary>
            <div>
                <ul><li>Liver stiffness &lt;6.4 kPa has a high NPV for ruling out advanced fibrosis.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Extra-hepatic Manifestations</strong></summary>
            <div>
                <ul><li>Iron-related damage can occur outside the liver.</li></ul>
                
        <details>
            <summary><strong>Bones &amp; Joints</strong></summary>
            <div>
                <ul><li>Osteoporosis: Odds Ratio of 2.30 in male C282Y homozygotes.</li><li>Arthritis: 27.9% of males require joint replacement vs. 17.1% of controls.</li><li>Recommendation: Consider baseline bone density scan in adults &gt;40 years.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Cardiac Disease</strong></summary>
            <div>
                <ul><li>Cardiomyopathy occurs in &lt;3% of C282Y homozygotes.</li><li>Primarily in those with serum ferritin &gt;1000 mg/L.</li><li>Recommendation: Cardiac testing (echo/MRI) warranted for ferritin &gt;2000 mg/L or severe iron overload.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Neurological Manifestations</strong></summary>
            <div>
                <ul><li>UK Biobank data shows ↑ risk of delirium, dementia, &amp; Parkinson’s disease in males.</li><li>Iron deposition in the brain has been reported on MRI.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Treatment</strong></summary>
            <div>
                <ul><li>Management focuses on removing excess iron, primarily via phlebotomy.</li><li>A correct diagnosis is essential to avoid unnecessary treatment.</li></ul>
                
        <details>
            <summary><strong>Benefits of Treatment</strong></summary>
            <div>
                <ul><li>Normalization of iron stores leads to:</li><li>- Improvement in fatigue.</li><li>- Reversal of liver fibrosis.</li><li>- Reduced risk of diabetes, cirrhosis, liver cancer, &amp; death.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Indications &amp; Urgency</strong></summary>
            <div>
                <ul><li>Initiate treatment without delay.</li><li>Urgent in symptomatic patients or those with ferritin &gt;1000 mg/L.</li><li>Beneficial even for moderate elevations (300-500 mg/L) → ↓ cardiovascular disease &amp; extra-hepatic cancers.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Phlebotomy for C282Y Homozygotes</strong></summary>
            <div>
                <ul><li>Standard of care for C282Y homozygotes with elevated serum ferritin.</li></ul>
                
        <details>
            <summary><strong>Protocol</strong></summary>
            <div>
                <ul><li>Induction: Weekly 500 mL phlebotomy.</li><li>Target: Serum ferritin in the low normal range (≈50 mg/L).</li><li>Side effects are minimal at experienced centers (local pain, syncope).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Maintenance Phase</strong></summary>
            <div>
                <ul><li>Need for maintenance varies by age, sex, and initial iron burden.</li><li>Voluntary blood donation is the ideal solution.</li><li>Many transfusion services now accept blood from hemochromatosis patients.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Non-expressing Homozygotes</strong></summary>
            <div>
                <ul><li>C282Y homozygotes with normal ferritin at diagnosis.</li><li>Unlikely to develop iron overload later in life.</li><li>Management: Observation with periodic ferritin checks every few years.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Management of Complications</strong></summary>
            <div>
                <ul><li>Focus on surveillance for hepatocellular carcinoma (HCC).</li></ul>
                
        <details>
            <summary><strong>Cirrhosis &amp; HCC Risk</strong></summary>
            <div>
                <ul><li>Established cirrhosis → mandatory 6-monthly ultrasound &amp; AFP for HCC screening.</li><li>Hazard Ratio for hepatic malignancies in C282Y homozygous males: 10.5 (95% CI, 6.6–16.7).</li><li>HCC in hemochromatosis is often poorly differentiated with worse outcomes.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Management of Other HFE Genotypes</strong></summary>
            <div>
                <ul><li>Includes C282Y/H63D compound heterozygotes &amp; H63D homozygotes.</li></ul>
                
        <details>
            <summary><strong>Clinical Significance &amp; Approach</strong></summary>
            <div>
                <ul><li>Large studies show no ↑ mortality or morbidity; patients can be reassured.</li><li>Mild ferritin elevation is almost always associated with cofactors (metabolic syndrome, alcohol).</li><li>Treatment: Promote voluntary blood donation &amp; manage metabolic risk factors.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Management of Elevated Ferritin w/ Normal HFE</strong></summary>
            <div>
                <ul><li>A very common clinical scenario; these patients rarely have true iron overload.</li></ul>
                
        <details>
            <summary><strong>Diagnostic Pathway</strong></summary>
            <div>
                <ul><li>If significant biochemical iron overload is suspected, MRI liver is preferred over a trial of phlebotomy.</li><li>If MRI confirms iron overload, refer to a specialist for advanced genetic testing (ferroportin, hemojuvelin, etc.).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Alternative &amp; Adjunctive Therapies</strong></summary>
            <div>
                <ul><li>Options beyond standard phlebotomy.</li></ul>
                
        <details>
            <summary><strong>Erythrocytaphoresis</strong></summary>
            <div>
                <ul><li>Automated red cell exchange.</li><li>Removes 2.3 times more iron per procedure than standard 500 mL phlebotomy.</li><li>Requires fewer treatments but has higher supply costs.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Dietary &amp; Other Therapies</strong></summary>
            <div>
                <ul><li>Iron-reduced diet: Minor effect.</li><li>English tea with meals: Can ↓ iron absorption.</li><li>Proton pump inhibitors: Can ↓ iron absorption but not enough to replace phlebotomy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Chelation Therapy</strong></summary>
            <div>
                <ul><li>Deferasirox (oral) has been studied but is not approved for hemochromatosis.</li><li>Less efficient than phlebotomy with more adverse effects.</li><li>Rarely used, typically in combination with phlebotomy for life-threatening cases.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Future Developments &amp; Controversies</strong></summary>
            <div>
                <ul><li>Evolving areas in diagnosis, screening, and treatment.</li></ul>
                
        <details>
            <summary><strong>Screening</strong></summary>
            <div>
                <ul><li>Population screening with C282Y genetic test remains controversial.</li><li>Whole genome testing could lead to a large number of new incidental diagnoses.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnostics</strong></summary>
            <div>
                <ul><li>Noninvasive markers for liver fibrosis need further study to optimize cutoffs specific to hemochromatosis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Novel Therapies</strong></summary>
            <div>
                <ul><li>Mini-hepcidin: Parenteral therapy that reduces intestinal iron absorption.</li><li>- Does not mobilize stored iron.</li><li>- Proposed for use after initial de-ironing to reduce need for maintenance phlebotomy.</li><li>Gene editing (CRISPR): Potential future cure, but likely to be developed for more severe diseases first.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
